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Objectives The aim of this study was to explore the incidence, causes, and outcomes of cardiac
tamponade in patients undergoing transcatheter aortic valve implantation (TAVI).
Background Use of TAVI is increasing, but the procedure is vulnerable to complications, given the
cohort of patients. Cardiac tamponade is a possible complication, and there is a scarcity of data on
the incidence and outcomes of cardiac tamponade during TAVI.
Methods All patients who sustained cardiac tamponade during or post-TAVI between 2007 and
2012 were included in the study.
Results Of 389 patients who underwent TAVI, 17 (4.3%) had cardiac tamponade. The mean age
was 82.3  3.7 years, and most were women (n  12, 70.6%). Causes of cardiac tamponade were
ight ventricular perforation by temporary pacemaker (9 patients, 52.9%), annular rupture or aortic
issection (4 patients, 23.5%), and tear in the left ventricular free wall caused by Amplatz stiff wire
r catheters (4 patients, 23.5%). Mortality occurred in 4 patients (23.5%), and all had tamponade
aused by injury to the high-pressured left-sided circulation (left ventricle and aorta). Most patients
n  14, 82.4%) sustained cardiac tamponade during the procedure—2 patients (11.7%) within 24 h,
and 1 patient after 24 h.
Conclusions Cardiac tamponade during TAVI is not frequent but is associated with high mortality
rates especially when left-sided structures are involved. Meticulous handling of the equipment and
improvements in the safety of currently used devices could further reduce the occurrence of this
complication. (J Am Coll Cardiol Intv 2012;5:1264–72) © 2012 by the American College of
Cardiology Foundation
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1265Transcatheter aortic valve implantation (TAVI) is a new
approach for the treatment of severe aortic stenosis (1,2).
The significant clinical benefit in high-risk elderly patients,
for whom few options were previously available, led to a
unique dissemination of TAVI. However, enthusiasm and
caution must be carefully balanced. Transcatheter aortic
valve implantation remains a complex and technically de-
manding procedure that requires advanced skills and inten-
sive training. Moreover, TAVI is associated with some
complications that need to be further reduced to improve
the procedural outcome. Cardiac tamponade is 1 such
complication, which is associated with high mortality.
This article reviews the presentation, frequency, timing,
and outcome of cardiac tamponade during TAVI and
discusses possible predisposing factors as well as our
suggestions to minimize the occurrence of this serious
complication.
Figure 1. CT Scan Demonstrating Distribution of Calcium on the
Aortic Valve
(A) Computed tomography (CT) scan exhibiting commissural calciﬁcationt
(arrows). (B) CT scan exhibiting annular calciﬁcation (arrows).Methods
Study design and patient population. This is a single-center,
retrospective observational cohort study of patients who devel-
oped cardiac tamponade during or after TAVI procedures.
From November 2007 to January 2012, 389 patients under-
went TAVI in our institution. Seventeen patients developed
cardiac tamponade defined as life-threatening slow or rapid
compression of the heart due to the pericardial accumulation of
fluid or blood because of effusion, trauma, or rupture of the
heart or surrounding structures (3,4).
Patient selection and risk stratiﬁcation. After evaluation by a
eam of cardiologists and cardiothoracic surgeons, patients
ith severe symptomatic aortic stenosis requiring aortic
alve replacement were considered for TAVI if the risk for
urgical aortic valve replacement was “high” according to the
ogistic European System for Cardiac Operative Risk Eval-
ation (EuroSCORE) (5) and the Society of Thoracic
Surgeons (STS) score (6) or if
they were considered “inopera-
ble” (7,8). All patients had se-
vere aortic valve stenosis with a
valve area1 cm2, with or with-
ut aortic valve regurgitation
nd a logistic EuroScore or STS
core 10% (5,6) or logistic Eu-
oScore 10% but considered
noperable. Pre-interventional
creening included transthoracic
chocardiography to confirm di-
gnosis and to evaluate the left
entricular (LV) dimensions and
olumes. Multi-slice computed
omography (MSCT) was per-
ormed to evaluate dimensions
nd calcification of aortic valve,
orta, peripheral vessels, and coronary anatomy. All patients
ave written informed consent for the procedure and data
ollection for research purposes. All patient, procedural, and
ollow-up data are prospectively entered into a dedicated
atabase by physicians directly involved with the procedure.
Overview of procedure. Two TAVI systems have seen wide
linical application: the balloon-expandable Edwards valve
Edwards Lifesciences, Irvine, California), and the self-
xpandable CoreValve ReValving system (Medtronic, Min-
eapolis, Minnesota). Both systems have been extensively
escribed elsewhere (9–11). Retrograde transarterial or
ntegrade transapical approaches are used to access the
ortic valve.
Retrospective analysis of MSCT. We retrospectively analyzed
nnular diameters (coronal and sagittal views), the trans-
erse view to calculate the annular eccentricity index in a
ulti-planar reconstruction in patients who had annular
Abbreviations
and Acronyms
EuroScore  European
System for Cardiac Operative
Risk Evaluation
LV  left ventricle/
ventricular
MSCT  multi-slice
computed tomography
RV  right ventricle/
ventricular
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantation
TPW  temporary
pacemaker wireears. The angle between the aortic root axis and the LV axis
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1266was calculated. Annular and commissural calcifications were
also evaluated to understand whether it has a relation with
annular tears (Figs. 1A and 1B).
Statistical analysis. Continuous variables are presented as
mean  SD and range. Continuous variables were com-
pared by Student t test (for the skewed data, Mann–
Whitney test was used), whereas categorical variables were
compared by chi-square tests or Fisher exact tests as
appropriate. Statistical analysis was performed with SPSS
(version 18 for Windows; SPSS, Inc., Chicago, Illinois).
Results
Of 384 patients, 17 (4.3%) developed cardiac tamponade
either during or post procedure. Patients who developed
tamponade were older than rest of the patients, with a mean
Table 1. Patient Characteristics and Surgical Risk S
Total Patients
(n  389)
Cardiac Tam
(n  17
Male sex 5 (29.4)
Age, yrs 82.5 3.6
Height, cm 159.2 5.4
Weight, kg 70.9 13.7
Body mass index 27.3 4.0
Body surface area, m2 1.71 0.13
Current smoker 0 (0)
Hypertension 14 (82.4)
Hypercholesterolemia 6 (35.3)
Diabetes 3 (17.6)
Insulin therapy 2 (11.8)
Renal insufﬁciency 2 (11.8)
Patients on dialysis 0 (0)
COPD 5 (29.4)
Peripheral arterial disease 5 (29.4)
Cerebrovascular disease 0 (0)
Coronary artery disease 6 (35.3)
Previous myocardial infarction 1 (5.9)
Previous PTCA/PCI 2 (11.8)
Previous CABG 0 (0)
Angina 2 (11.8)
Syncope 0 (0)
Baseline creatinine 0.93 (0.84–1.2
Creatinine clearance at admission 46.2 19.2 m
Baseline Hb 12.0 1.9 m
Porcelain aorta 5 (29.4)
EuroScore standard, % 9.6 3.0
Logistic EuroScore 13.8 (9.0–23.4
STS score 6.7 (4.5–9.3)
STS morbidity and mortality 27.7 (20.9–32.
Values are mean SD or median (interquartile range) n (%), unless o
COPD chronic obstructive pulmonary disease; CABG coronary
Evaluation; Hb  hemoglobin; PCI  percutaneous coronary int3; te
Society of Thoracic Surgeons.age of 82.5  3.6 years versus 79.2  7.7 years, respectively(p value  0.07), and most were women (n  12, 70.5%).
Tamponade occurred in patients who were relatively shorter
compared with the rest of the patients who did not develop
tamponade (159.2  5.4 cm vs. 164.6  8.3 cm; p  0.01).
Mean standard EuroSCORE, Logistic EuroSCORE, and
STS score were 9.6  3.0%, 13.8% (9.0% to 23.4%), 6.7%
(4.5% to 9.3%), respectively. The STS score for morbidity
and mortality was 27.7% (20.9% to 32.4%). The rest of the
demographic data are described in detail in Table 1. Details
of the aortic valve and LV measurements are tabulated in
Online Table 1. No significant differences were detected
between patients who developed tamponade versus those
who did not in terms of demographic and echocardio-
graphic data.
Procedural data. In the 17 patients who developed tampon-
e No Cardiac Tamponade
(n  372) p Value
183 (49.2) 0.06
79.2 7.7 0.07*
164.6 8.3 0.01
69.3 10.9 0.65*
26.1 4.7 0.21*
1.77 0.19 0.23
12 (3.2) 1.0†
265 (71.2) 0.77†
223 (60.1) 0.04
108 (29.0) 0.27
36 (9.6) 0.67†
118 (31.7) 0.07
13 (3.4) 1.0†
127 (34.1) 0.69
108 (29.0) 1.0†
52 (13.9) 0.14†
147 (39.5) 0.77
78 (20.9) 0.22†
75 (20.2) 0.54†
78 (20.9) 0.03†
107 (28.8) 0.10
61 (16.4) 0.09†
dl 1.04 (0.84–1.44) mg/dl 0.29*
52.7 24.2 ml/min 0.32
12.0 1.7 mg/dl 0.64*
62 (16.7) 0.17†
10.6 2.9 0.11*
19.7 (11.4–31.9) 0.08*
5.9 (3.9–10.0) 0.71*
27.8 (21.6–40.0) 0.78*
indicated. *Wilcoxon test; †Fisher exact test.
ypass graft; EuroScore European System for Cardiac Operative Risk
n; PTCA  percutaneous transluminal coronary angioplasty; STS core
ponad
)
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1267(41.2%) Edwards Sapien XT through transfemoral ap-
proach, and 2 (11.7%) Edwards Sapien through transapical
approach (Table 2). Amplatz 0.35-inch Extrastiff guidewire
(Cook Medical, Inc., Bloomington, Indiana) was used for
delivery of all Edwards bioprosthetic valves. Corevalve
(Medtronic) was implanted in 8 patients (47.1%)—1 (5.8%)
through transaxillary approach, and the rest through trans-
femoral approach. Amplatz 0.35-inch Superstiff guidewire
(Boston Scientific, Natick, Massachusetts) was used to
deliver all Corevalves.
Pre-dilation was performed in 10 patients (58.8%) with a
mean balloon size of 22.5  1.1 mm, whereas post-dilation
was done in 5 patients (29.4%) with a mean balloon size of
25.33  4.04 mm.
Types, presentation, and outcome. The causes of tampon-
Table 2. Procedural Data
Total Patients
(n  389)
Cardiac Tamponad
(n  17)
Type of anesthesia
Sedation 14 (82.4)
General anesthesia 3 (17.6)
Type of temporary pacemaker wire
Screw-in lead 4 (23.5)
Passive leads with a balloon 11 (64.7)
Epicardial lead 2 (11.7)
Prosthesis size, mm 26.0 2.0
23-mm valve 3 (17.6)
26-mm valve 9 (52.9)
29-mm valve 4 (23.5)
31-mm valve 1 (5.8)
Sheath size (F) 18.9 1.9
CoreValve 8 (47.1)
Edwards valve 9 (52.9)
Edwards Sapien XT 7 (41.2)
Edwards Sapien 2 (11.7)
Femoral approach 14 (82.3)
Transapical 2 (11.7)
Trans axillary 1 (5.8)
Guidewires
Amplatz Extra stiff 0.35” 9 (52.9)
Amplatz Superstiff 0.35” 8 (47.1)
TAVI in bioprosthesis, mm 1 (5.8) (23, pericarbo
Pre-dilation 11 (64.7)
Pre-dilation balloon diameter, mm 22.8 1.5
Post-dilation 5 (29.4)
Post-dilation balloon diameter, mm 24.4 3.8
Elective percutaneous closure 14 (82.3)
Elective surgical closure 3 (17.6)
Device success VARC 15 (88.2)
Values are mean SD or median (interquartile range) n (%), unless o
TAVI transcatheter aortic valve implantation; VARC Valve Acadde were classified according to the site of origin. sANNULAR TEAR. Of the 17 patients with tamponade, 3
17.6%) had annular tears (Fig. 2). In the first case,
re-dilation was performed with a 23-mm balloon, followed
y implantation of a 26-mm Edwards valve. Angiographic
ontrol revealed annular tear in relation to the left coronary
usp, and echocardiography showed signs of cardiac tam-
onade. Pericardiocentesis was done after, in which a
rainage tube was inserted with auto-transfusion in the
emoral vein. A trial to seal that annular tear with another
alve was done but was unsuccessful. The patient sustained
ardiac arrest and could not be resuscitated.
In the second case, the annular rupture occurred after
ost-dilation of a 29-mm Core valve with a 26-mm balloon.
ercutaneous pericardiocentesis was performed, which sta-
ilized the condition of the patient. However, the patient
No Cardiac Tamponade
(n  372) p Value
1.0*
301 (80.9)
71 (19.1)
13 (3.5) 0.005*
336 (90.3) 0.006*
23 (6.2) 0.43*
26.1 2.2 0.45
89 (23.9) 0.57*
183 (49.2) 0.8
94 (25.3) 1.0*
6 (1.6) 0.35*
19.5 2.2 0.77†
152 (40.9) 0.38
220 (59.1) 0.38
309 (83.1) 0.7*
25 (6.7) 0.3*
38 (10.2) 1.0*
220 (59.1) 0.38
152 (40.9) 0.38
14 (3.8) 0.46*
307 (82.5) 0.10*
21.9 1.8 0.05†
86 (23.1) 0.56*
Pre-dilation balloon diameter, mm 25.3 2.5 0.52†
301 (80.9) 1.0*
71 (19.1) 1.0*
333 (89.5) 0.34*
indicated. *Fisher exact test; †Wilcoxon test.
search Consortium.e
n)
therwise
emic Reustained cardiac arrest 7 days later and could not be
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1268resuscitated. The cause of death was unclear, but electrolyte
disturbance was suspected.
In the third case, annular rupture was encountered after
deployment of a 26-mm Edwards Sapien XT valve, which
was immediately recognized, and prompt intervention (in
the form of percutaneous pericardiocentesis) successfully
stabilized the patient.
LV TEARS. Four (23.5%) patients had LV tear during
TAVI (Fig. 3). In 2 patients, the LV tear was diagnosed on
ventriculography, which exhibited extravasation of contrast
into the pericardium. In the other 2 patients, the diagnosis
was confirmed on surgical exploration, performed for ongo-
ing bleeding despite pericardiocentesis.
The first patient developed tamponade after implantation
of a 29-mm Corevalve, and the LV tear was caused by the
Amplatz Superstiff wire. Pericardiocentesis was not suffi-
cient, and hence surgical closure was necessary.
The second patient developed tamponade after implan-
tation of a 23-mm Edwards valve. The tear was probably
caused by the nose cone of the delivery system, which was
advanced too distally with poor wire support. Pericardio-
centesis was not sufficient, as with the first patient, and
hence surgical repair was necessary.
The third patient had an LV tear caused by the Amplatz
Extrastiff wire. The perforation occurred after implantation
of a 23-mm Edwards valve. Surgical exploration revealed a
rather large tear in the LV free wall, requiring surgical stitch
closure. The patient had an unstable post-operative course:
developed sepsis and multi-organ failure and died 10 days
later. The fourth patient developed cardiac tamponade
during wire exchange from the floppy to Amplatz Super stiff
Figure 2. Aortography Demonstrating Annular Tear
Extravasation of contrast around the aortic annulus during aortography,
indicative of annular tear (arrow).wire. The perforation was successfully repaired surgically.RIGHT VENTRICULAR PERFORATIONS. Nine patients
(52.9%) had tamponade due to right ventricular (RV)
perforation, and all were caused by temporary pacemaker
wires: 4 (23.5%) with a screw-in-lead, 3 (17.6%) with
passive leads, and 2 (11.7%) with epicardial leads.
Tamponade after suspected aortic dissection. One patient
had tamponade 24 h after the procedure. A 26-mm Ed-
wards valve was implanted, after pre-dilation with a 23-mm
balloon, in a patient with a bicuspid aortic valve. There were
no immediate post-procedural complications; however, the
patient developed hemodynamic instability on the following
day. Bedside echocardiography revealed massive pericardial
effusion, and aortic dissection was suspected. The patient
sustained cardiac arrest before an effective treatment was
established, and prolonged resuscitation was unsuccessful.
Timing. Most patients (n  14, 82.3%) developed cardiac
tamponade during the procedure: 3 (17.6%) due to
annular tear, 4 (23.5%) due to LV tear, and 7 (41.2%) due
to RV perforations. Two patients had tamponade within
24 h. Both were due to RV perforations and promptly
responded to pericardiocentesis. One patient developed
tamponade 1 day after the procedure, probably due to
aortic dissection; the details have been presented in the
previous section (Table 3).
Post-dilation. Post-dilation was done in 5 (29.4%) of 17
patients with tamponade, 2 of which resulted in annular
rupture/aortic dissection, and 3 had RV perforations, which
were probably not related to post-dilation (Online Table 2).
Mortality. Four patients died after tamponade (23.5%);
causes were LV tear, annular tear, and suspected aortic
dissection. All mortality occurred in patients who developed
bleeding from the arterial side of the circulation, and none
occurred from RV perforations.
Figure 3. Left Ventricular Free-Wall Tear
Left ventricular free-wall tear noted during surgical exploration after cardiac
tamponade during transcatheter aortic valve implantation.
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1269MSCT analysis. Retrospective analysis of the computed to-
ography scans of patients with annular rupture revealed
resence of both commissural (of at least 2 commissures)
nd annular calcification (Online Table 2). Interestingly,
atients who had annular rupture had both commissural (of
t least 2 commissures) and annular calcification.
iscussion
The main findings of this study are: 1) the incidence of
cardiac tamponade was 4.3%; 2) the most common cause
was RV perforation due to pacemaker leads; 3) other causes
of tamponade were perforations in the arterial side almost
equally divided between annular/supra-annular ruptures and
LV perforations; 4) all perforations occurring in the RV
could be treated with pericardiocentesis, whereas open
surgery was needed in the arterial perforations; and 5) no
death occurred after RV perforation, whereas the mortality
after arterial perforation was 50%.
The 4.3% incidence of cardiac tamponade reported in our
experience is not higher than in other cardiac interventions,
such as pacemaker insertion, atrial fibrillation ablation, and
so forth (12). However, mortality after tamponade was high
with a rate of 23.5% in our cohort, which reflects the
vulnerability of the patient cohort, because they are usually
elderly and frail with multiple comorbidities. In particular,
the severe consequences of arterial perforation with an
Table 3. Cardiac Tamponade, Timing, Presentation, and Follow-Up
Total Patients
(n  17)
Timing of presentation
During/immediately at end of procedure 14 (82.4)
20 min after procedure 1 (5.8)
1 h after procedure 1 (5.8)
1 day after procedure (query aortic dissection) 1 (5.8)
Type of rupture
Annular rupture 3 (17.6)
Probable aortic dissection 1 (5.8)
LV free wall rupture 4 (17.6)
RV perforation 9 (52.9)
Percutaneous pericardiocentesis only 12 (70.6)
Pericardiocentesis  surgical intervention 5 (29.4)
LV tears 3 (17.6)
RV tears (mini-sternotomy) 1 (5.8)
Average amount of effusion drained, ml 362.5 179.7
Mortality 4 (23.5)
Time of mortality
1 day post-procedural 2 (11.7)
7 days post-procedural 1 (5.8)
10 days post-procedural 1 (5.8)
Values are n (%), unless otherwise indicated.
LV left ventricular; RV right ventricular.almost universal need for surgical intervention and a mor- itality of 50% impose the need to eliminate this kind of
complication.
There are many predisposing factors for the development
of tamponade during TAVI: calcified aortic annulus, and
fragile and scarred myocardium due to likely co-existence
of ischemic heart disease with previous infarcts. It is also
related to the devices, technique, and experience of the
operator. However, some of these factors are avoidable.
Technically, there are 5 steps in the procedure.
Step “1,” introduction of the temporary pacemaker wire into
the RV. A significant proportion of our cardiac tamponade
ccurred due to temporary pacemaker, especially with the
crew-in lead. In our study, 9 patients (52.9%) had RV
erforations, of which 4 had screw-in leads. Mahapatra et
l. (13) demonstrated that use of screw-in leads was an
ndependent risk factor for having RV perforation. How-
ver, the rationale behind using screw-in lead pacemaker
as to have a stable position and threshold during the time
f balloon inflation and valve deployment. In addition, even
ith passive wire we were probably more aggressive in
ositioning to achieve best threshold. It is also well-
ocumented that elderly patients are more prone for com-
lications such as RV rupture after temporary pacemaker
ire (TPW) insertion than younger patients due to thinned
V. After significant cases of tamponade from TPW, we
ntroduced changes to our practice. Only passive TPW were
sed, and we were less aggressive in manipulating the wire,
hich resulted in significant reduction in occurrence of
amponade in the recent cohort (2 patients between 2011
nd 2012 vs. 7 patients between 2007 and 2010). Hence,
his could be attributable to our learning curve. Passive
PW should be first choice, and screw-in lead should only
e considered if there are issues with stable positioning of
he lead, threshold, and sensitivity.
Step “2,” introduction of the stiff wire in the LV cavity; and
step “3,” introduction of the delivery system of the valve
along the stiff wire. Amplatz stiff wire provides excellent
upport for delivery of the valve and is a vital component of
he procedure (Fig. 4). However, due to the stiffness of the
ire, it has the potential of causing significant trauma to the
V myocardium. Even if the operators perform an appro-
riate curve on the distal stiff end of the wire, the curve itself
an cause a linear perforation of the LV, when the wire
upported by the delivery system advances too distally in a
mall LV cavity. In our study, 4 patients (23.5%) had LV
ears, mostly attributed to stiffness of the wire curvature. It
s not uncommon that the operators focus exclusively on the
rea of valve deployment, especially during positioning and
eployment phase. This might briefly divert the attention
rom the stiff wire in the LV that could migrate and cause
atastrophe. Hence great caution is necessary during intro-
uction of Amplatz stiff wire in the LV.
In an aim to provide a cushioning effect to the stiff wiren the LV, we have adopted a new trick: “cushioned stiff
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1270wire” technique. The idea is based on the fact that the curve
of the Amplatz stiff wire acts as a sharp blade, and
accordingly, we intended to cover the distal part of wire with
a pig-tail catheter to make it less aggressive, especially when
it comes in contact with the wall of LV. Details of how to
Figure 4. Positioning of Valve
Fluoroscopic image demonstrating nose cone of the Edwards’ delivery sys-
tem and narrow-curved Amplatz stiff wire (potential sources for left ventric-
ular [LV] tear).
Figure 5. Steps Involved in Making “Cushioned Stiff Wire”
(A) Distal edge of 6-F pigtail catheter. (B) Stiff wire inserted through distal pig
catheter. (D) Fluoroscopic image showing “Cushioned Stiff Wire” inside the left ventmake this wire are given (Fig. 5): 1) cut the distal segment
of a 6-F pigtail catheter (approximately 3 cm); 2) insert and
position the cut segment of the pigtail catheter on the distal
part of the Amplatz stiff wire just overlapping onto the soft
portion of the wire; and 3) the pigtail catheter is then
splinted by 2.0 silk sutures, which are tied on the wire,
proximal and distal to the pigtail.
The end result is a smooth and soft curved wire, which
is relatively less traumatic to the LV. In addition, the
proximal knot on the wire also acts as a barrier against the
forward advancement of the delivery system, preventing
nose cone injury. The wire is then delivered into the LV
with a 90-cm 6-F sheath. This new technique has now
been regularly used at our center with over 50 cases to
date, and we have not had any cases of tamponade from
LV tear. This unsophisticated technique is an interim
measure while we wait for the availability of a dedicated
modified wire.
Step “4,” deployment of the valve. This specifically applies
to the balloon expandable-valve and to post-dilation of any
valve. The retrospective analysis of the computed tomogra-
phy scan in patients with annular tear demonstrated signif-
icant annular and commissural calcifications. Although we
could not correlate calcification with annular tear, due to
small number of patients, nevertheless the degree of annular
and commissural calcification might be the predictor for
theter. (C) Distal and proximal knots with silk sutures to secure the pigtailtail ca
ricular cavity.
Table 4. Summary Table for All Cases
Patient
No.
Log.
EuroSCORE %
Valve
Type
Valve Size
(mm) Stiff Wire TPW Post-Dilation
Post-Dilation
Balloon Size (mm) Type of Tear
Time of
Presentation Management Mortality
1 7.94 Corevalve 26 Amplatz Superstiff Screw-in lead Yes 23 RV On table Percutaneous pericardiocentesis No
2 22.52 Corevalve 26 Amplatz Superstiff Screw-in lead Yes 23 RV On table Percutaneous pericardiocentesis No
3 16.81 Corevalve 26 Amplatz Superstiff Screw-in lead No RV 1 h later Percutaneous pericardiocentesis No
4 10.76 Corevalve 29 Amplatz Superstiff Passive lead No RV 20 min later Percutaneous pericardiocentesis
Mini-sternotomy
No
5 3.26 Corevalve 29 Amplatz Superstiff Passive lead No LV On table Percutaneous pericardiocentesis
surgical closure
No
6 21.20 Corevalve 29 Amplatz Superstiff Passive lead No RV On table Percutaneous pericardiocentesis No
7 36.33 Corevalve 29 Amplatz Superstiff Passive lead Yes 26 Annular tear On table Percutaneous pericardiocentesis Yes
8 7.03 Corevalve 31 Amplatz Superstiff Passive lead No LV On table Percutaneous pericardiocentesis
surgical closure
No
9 8.97 Edwards 23 Amplatz Extrastiff Passive lead No LV On table Percutaneous pericardiocentesis
surgical closure
No
10 80.36 Edwards 23 Amplatz Extrastiff Passive lead No RV On table Percutaneous pericardiocentesis No
11 24.18 Edwards 23 Amplatz Extrastiff Passive lead No LV On table Percutaneous pericardiocentesis
surgical closure
Yes
12 25.13 Edwards 26 Amplatz Extrastiff Passive lead Yes 26 Annular tear On table Percutaneous pericardiocentesis Yes
13 8.97 Edwards 26 Amplatz Extrastiff Epicardial lead
(Transapical)
No RV On table Percutaneous pericardiocentesis No
14 14.15 Edwards 26 Amplatz Extrastiff Passive lead No Annular tear On table Percutaneous pericardiocentesis No
15 9.76 Edwards 26 Amplatz Extrastiff Screw-in lead No RV On table Percutaneous pericardiocentesis No
16 13.8 Edwards 26 Amplatz Extrastiff Passive lead No Probable aortic
dissection
1 day later Percutaneous pericardiocentesis Yes
17 11.29 Edwards 26 Amplatz Extrastiff Passive lead No RV On table Percutaneous pericardiocentesis No
EuroScore European System for Cardiac Operative Risk Evaluation; LV left ventricular; RV right ventricular; TPW temporary pacemaker wire.
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1272annular tear. Caution should be taken in choosing the valve
size especially in patients with heavy annular calcification; it
might be that choosing a smaller valve in such patients
would be safer. In addition the angle between aortic root
axis and LV axis should be considered. Increase in the
angulation tends to direct the delivery system on to the wall
of the LV rather than into the cavity, which can force the
stiff wire or the nose-cone to dissect through the LV free
wall.
Step “5,” post-dilation after valve deployment. Two-thirds
f our patients who had annular rupture underwent post-
ilation with relatively larger balloons (Online Table 2). It
ight be safer to initiate with a smaller balloon and proceed
urther after thorough evaluation at every step.
To summarize, there are 2 main determinants of cardiac
amponade in patients undergoing TAVI: 1) equipment
nd materials used, and 2) patient risk factors. With
egard to the equipment, it seems that there is room to
mprove the ancillary equipment. We can minimize
rauma by selecting less aggressive devices, such as passive
emporary pacemaker wires over screw-in leads, and
ake stiff wire more user-friendly. With regard to patient
isk factors (most of which are unavoidable), annular size,
nnular calcification, commissural calcification, LV size,
V hypertrophy, and myocardial ischemia/scar must all
e thoroughly evaluated before the procedure. Finally, it
s crucial to emphasize the experience of the operator, and
earning curve is extremely important to reduce the
omplication rate.
Study limitations. This study is a single-center retrospective
nalysis. Although we have speculated possible predictors
or tamponade, we could not analyze or correlate the
redictors, due to the small number of patients with
amponade. Nevertheless, this study might lead future
rojects of combining data from various centers (Table 4).
onclusions
Cardiac tamponade, although not commonly encountered,
remains 1 of the serious complications of TAVI with a
relatively high mortality. The most common cause of
tamponade is from RV rupture related to transient pace-
maker wire followed by LV and annular ruptures, which are
attributable to Amplatz stiff wire and delivery device.
Meticulous selection and handling of currently available
devices should minimize occurrence of cardiac tamponade.Reprint requests and correspondence: Dr. Antonio Colombo,
EMO-GVM Centro Cuore Columbus, Interventional Cardiology
Unit, San Raffaele Scientific Institute, 48 Via M. Buonarroti,
20145 Milan, Italy. E-mail: info@emocolumbus.it.
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